Australian researchers develops a new potential treatment for DIPG

With almost around 20 Australian children succumbing to fatal brain tumor, DIPG (Diffuse Intrinsic Pontine Glioma) every year, the need for a potential treatment has become imminent. Recently, a researcher from the Children’s Cancer Institute and Sydney Children’s Hospital released his study and papers that focus on the development of a revolutionary drug combination with is touted to be highly effective in the treatment of cancer cells in the body.

In a paper published in the journal Nature Communications, lead researcher and pediatric oncologist, Associate Prof. Ziegler from the Sydney Children’s Hospital and Children’s Cancer Institute revealed the drug therapy, which is currently in the nascent stages of trials in adult cancer.

The potential drug, which is a blend of two drugs- AMXT 1501, and DFMO (difluoromethyleornithine), has been deemed to be the most efficient treatment ever tested in lab models of the incurable DIPG cancer. 

According to reliable reports, Zeigler and his team members have enunciated the development of Australia’s first research program into DIPG by making use of tumor cells donated by the parents of children who have lost their lives to this fatal cancer.

With use of this, the team created the first laboratory models of the tumor to test new drugs, allowing them to conclude that treatment via AMXT 1501, would potently block the movement of polyamines into cancer cells.

It would be essential to note that the novel research study was supported by grants from various organization including the DIPG Collaborative, National Health and Medical research council, Cancer Institute NSW, Cure Brain Cancer Foundation, and others, with drug supply from Aminex Therapeutics, Inc.

Commenting on the revolutionary breakthrough, Dr. Mark R. Burns, President, Founder, and CSO at Aminex Therapeutics and an inventor of AMXT 1501 stated that the dynamic results against DIPG disease put forth by Dr. Ziegler and his team of researchers add huge potential to the company’s inspiration to see these findings replicated against human cancers. He added that the firm hopes that this treatment would make a notable difference in lives of those with DIPG and other cancers.

Source Credit: